| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8776717 | The Breast | 2018 | 6 Pages |
Abstract
Neoadjuvant ddAC-wTCb is less tolerable in clinical practice compared to most clinical trials, with a pCR comparable to historic rates using non-platinum regimen. The role of Cb in neoadjuvant chemotherapy for BRCA mutated TNBC remains uncertain.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Tal Sella, Einav Nili Gal Yam, Keren Levanon, Tal Shapira Rotenberg, Moran Gadot, Iryna Kuchuk, Rinat Bernstein Molho, Amit Itai, Tami Mekel Modiano, Raya Gold, Bella Kaufman, Shani Paluch Shimon,